Other
Exhibit 99.1  Gemini Therapeutics Announces Initial Data from its Ongoing Phase 2a Study of GEM103 in
Gemini Therapeutics Announces Initial Data from its Ongoing Phase 2a Study of GEM103 in
This is the opening of the release as filed. Read the full document on SEC.gov, or read it in full on SPAC Watch with the trust, deadline and warrant terms alongside it.
Every SPAC announcement, read and classified.
Announcements are pulled from 8-K exhibits as they are filed, classified by what they announce, and attached to the SPAC they belong to.
No card requiredSourced directly from EDGAR